Hubei Biocause Pharmaceutical Co., Ltd.

    Hubei Biocause Pharmaceutical Co., Ltd.

    SSZSE:000627
    1.58
    CNY
    0.00
    (0.00%)
    2011 Y
    2012 Y
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    TTM
    Revenue per Share
    0.84
    0.59
    0.72
    0.58
    0.4
    4.2
    12.02
    6.27
    10.14
    8.77
    10.45
    10.79
    9.89
    8.52
    Basic EPS, GAAP
    -0.08
    0.01
    -0.08
    0.06
    0.18
    0.44
    0.3
    0.27
    0.36
    0.12
    0.1
    0.06
    -0.13
    -0.16
    Free Cash Flow per Basic Share
    -0.06
    -0.03
    -0.01
    -0.22
    -0.06
    -1.49
    -0.08
    2.99
    5.65
    4.37
    0.83
    1.62
    1.89
    -0.01
    Dividend per Share
    0.02
    0.02
    0.02
    0.02
    0.02
    0.03
    0.03
    0.06
    0.05
    0.13
    0.08
    0.15
    0.28
    0.15
    Book Value per Share
    0.94
    0.98
    0.92
    0.94
    1.12
    1.53
    1.83
    1.87
    2.18
    2.24
    2.39
    2.51
    2.04
    2.01
    Tangible Book Value per Share
    0.76
    0.88
    0.78
    0.71
    0.94
    3.38
    4.52
    3.99
    5.69
    5.83
    6.59
    6.15
    5.42
    5.98
    Basic Weighted Avg Shares
    1,356
    1,314
    1,347
    1,397
    1,374
    4,043
    4,421
    4,913
    4,933
    4,836
    4,707
    4,568
    5,014
    4,938
    Sales/Revenue/Turnover
    1,134
    780
    968
    806
    556
    16,989
    53,152
    30,805
    50,042
    42,433
    49,175
    49,264
    49,593
    42,082
    Operating Margin (%)
    -5.14
    -4.79
    -8.6
    -11.68
    -10.16
    50.47
    46.12
    86.35
    22.68
    8.43
    64.74
    62.92
    43.78
    17.06
    Depreciation Expense
    63
    52
    69
    74
    65
    139
    123
    93
    79
    64
    134
    147
    152
    - -
    Net Income, GAAP
    -102
    12
    -101
    84
    247
    1,779
    1,326
    1,327
    1,776
    580
    471
    274
    -652
    -772
    Effective Tax Rate (%)
    - -
    7.94
    - -
    22.79
    25.09
    9.43
    1.69
    9.83
    19.68
    22.87
    - -
    - -
    - -
    56.66
    Profit Margin (%)
    -8.97
    1.52
    -10.44
    10.39
    44.48
    10.47
    2.5
    4.31
    3.55
    1.37
    0.96
    0.56
    -1.31
    -1.83
    Working Capital
    235
    35
    -266
    -184
    -134
    15,925
    17,107
    23,307
    17,351
    43,727
    37,299
    30,992
    26,204
    17,751
    LT Debt
    123
    23
    - -
    - -
    42
    360
    41
    111
    - -
    2,830
    6,204
    6,878
    7,171
    5,579
    Total Equity
    1,414
    1,537
    1,418
    1,490
    1,784
    20,398
    26,705
    26,015
    34,353
    34,588
    37,475
    34,603
    33,634
    36,005
    Return on Invested Capital (%)
    - -
    -1.86
    - -
    -3.86
    -2.11
    63.87
    85.02
    73.15
    25.38
    6.66
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    2.1
    - -
    6.01
    14.13
    5.44
    -0.14
    1.25
    -43.38
    -0.42
    - -
    - -
    - -
    -0.08
    Return on Common Equity (%)
    -7.69
    0.93
    -8.02
    6.57
    17.32
    46.08
    18.59
    15.36
    17.8
    5.37
    4.26
    2.41
    -6.01
    -7.49

    Capital Structure

    CNY

    •

    in mil. unless spec.
    Mar'24
    Jun'24
    Sep'24
    ST Debt
    16,588
    10,930
    11,976
    LT Borrowings
    7,206
    5,510
    5,510
    LT Finance Leases
    54
    59
    69
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    4,941
    4,941
    4,941
    Market Capitalization
    12,198
    8,642
    18,321

    Working Capital

    CNY

    •

    in mil. unless spec.
    Mar'24
    Jun'24
    Sep'24
    Total Current Assets
    44,632
    35,297
    35,199
    Cash, Cash Equivalents & STI
    23,028
    13,487
    10,570
    Accounts Receivable, Net
    103
    107
    99
    Inventories
    4,295
    4,357
    3,871
    Total Current Liabilities
    23,537
    17,082
    17,448
    Payables & Accruals
    - -
    - -
    - -
    ST Debt
    16,588
    10,930
    11,976
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    CNY

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    112.73%
    6.12%
    -2.8%
    Free Cash Flow
    459.65%
    20.4%
    28.12%
    Net Income, GAAP
    17.4%
    -86.38%
    -337.82%
    Sales/Revenue/Turnover
    314.34%
    12.8%
    0.67%
    Total Cash Common Dividend
    77.99%
    57.03%
    102.03%

    Quarterly Revenue

    CNY

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    18,131
    9,206
    10,169
    11,758
    49,264
    2023
    21,902
    11,456
    7,684
    8,551
    49,593
    2024
    17,460
    11,559
    4,512
    - -
    - -

    Quarterly Earnings Per Share

    CNY

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    0.03
    - -
    - -
    - -
    0.06
    2023
    0.01
    - -
    - -
    - -
    -0.13
    2024
    -0.02
    - -
    - -
    - -
    - -

    Quarterly Dividends Per Share

    CNY

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    0.02
    - -
    - -
    - -
    0.15
    2023
    0.03
    - -
    - -
    - -
    0.28
    2024
    0.03
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business